The presentation of positive data for a key product like anthracycline by Moleculin Biotech, Inc. is likely to be viewed favorably by investors, potentially leading to increased investor confidence and a positive impact on the stock price in the short term. Given the significance of product development milestones in the biotech industry, such news is highly relevant and important for investors in MBRX.